Angiotensin News and Research

RSS

Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

An interesting preprint research paper describes structural changes resulting from the multiple mutations found in the recent Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is the causative agent behind the coronavirus disease 2019 (COVID-19) pandemic. In addition, the research describes the consequent effects of these changes on Omicron’s infectivity and immune evasion capabilities.

5 Jan 2022

Transplant recipients benefit from a COVID-19 vaccine booster

A new preprint research paper posted to the medRxiv* server describes the reduction in humoral immunity in SOTR following vaccination, as well as the improvement with an additional dose of the vaccine.

4 Jan 2022

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

A new study, published on the medRxiv* preprint server, investigated the changes in SARS-CoV-2 antibody levels among HCWs after SARS-CoV-2 vaccination. The study also assessed whether low responders produced sufficient SARS-CoV-2 anti-spike and neutralizing antibodies.

4 Jan 2022

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

Researcers determine the risk of symptomatic and asymptomatic SARS-CoV-2 infection on post-acute cardiovascular events and all-cause mortality.

4 Jan 2022

A closer look at the relationship between COVID-19 and Alzheimer’s disease

Researchers discuss the findings of previous studies on the role of SARS-CoV-2 infection in the progression of Alzheimer's Disease.

4 Jan 2022

The impact of natural selection on sequence diversity in SARS-CoV-2

Recent genomic analysis demonstrates that the SARS-CoV-2 genome is under two distinct selective forces.

3 Jan 2022

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Researchers investigate the capacity of vaccine-induced antibodies to generate Fc-effector activity against the SARS-CoV-2 Omicron variant.

3 Jan 2022

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Researchers combine SARS-CoV-2 spike vaccination with single-cell B-cell receptor sequencing technology to discover neutralizing antibody candidates.

3 Jan 2022

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

A new study provides detailed information about the molecular level binding interaction pattern of the SARS-CoV-2 Omicron and wt variant with the hACE2 receptor

31 Dec 2021

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

A new study used in silico approaches for designing a next-generation CD40-targeting vaccine, CD40.

31 Dec 2021

How much do mutations reduce vaccine effectiveness in the Omicron variant?

In new research, scientists from Adaptive Biotechnologies have been investigating the impact of spike protein mutations on vaccine efficiency for the Omicron variant. The study is currently available on the medRxiv* preprint server while awaiting peer review.

30 Dec 2021

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

New study findings show that the clinical-grade soluble ACE2 effectively inhibits the SARS-CoV-2 Omicron variant, which proves the principle of an effective therapeutic approach against Omicron-driven COVID-19 infections.

30 Dec 2021

An integrated computational methodology for COVID drug prioritization

Researchers recently published a study in the journal Briefings in Bioinformatics wherein they integrated multiple bioinformatics and cheminformatics-based methods to prioritize drugs for the treatment of COVID-19.

29 Dec 2021

Omicron analysis shows no clear evidence for increased virulence or lethality

Researchers conducted a genomic sequencing and epidemiological correlation analysis of the SARS-CoV-2 Omicron variant.

29 Dec 2021

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

Researchers determine the serum neutralizing and binding activity against the SARS-CoV-2 Omicron variant in individuals with different levels of immunity.

29 Dec 2021

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

A new study found that the presence of a subset of antibodies with broad neutralizing activities against all circulating variants of concern in the three-dose vaccines' memory B-derived antibody repertoire suggests that the Omicron/future variants infection may elicit selective and rapid recall of humoral responses, conferring secondary protection directed by memory etched in the immune system.

29 Dec 2021

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Now in new research, scientists from the University of Leicester have been investigating how these mutations alter the affinities of RBDs to ACE2.

28 Dec 2021

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Researchers from the University of Colorado Anschutz Medical Campus have been investigating the changes imparted on the Gamma variant by three RBD mutations.

28 Dec 2021

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

A recent study by a team of European researchers demonstrated how antibodies induced by currently circulating influenza A H1N1 strains can cross-react with the important part of the SARS-CoV-2 spike glycoprotein that interacts with the human cell receptor. Their paper is currently available on the medRxiv* preprint server while it undergoes peer review.

28 Dec 2021

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

The Omicron spike is relatively poorly cleaved and impaired in mediating cell-cell fusion and syncytia formation, contrary to predictions.

28 Dec 2021

Angiotensin News and Research

Further Reading

Scientists provide a structural framework for Omicron immune evasion and ACE2 receptor recognition

Transplant recipients benefit from a COVID-19 vaccine booster

BNT162b2 provides low vaccine responders adequate anti-spike and neutralizing antibodies to prevent SARS-CoV-2

Both symptomatic and asymptomatic COVID-19 associated with increased risk of cardiovascular events

A closer look at the relationship between COVID-19 and Alzheimer’s disease

The impact of natural selection on sequence diversity in SARS-CoV-2

Omicron spike-specific binding antibodies attenuate disease, despite increasing transmission

Humanized antibody shows strong neutralization ability against SARS-CoV-2 Delta variant

Exploring the increase in hACE2 binding affinity of SARS-CoV-2 Omicron variant

Impact of a pan-sarbecovirus dendritic-cell targeting vaccine on SARS-CoV-2 variants

How much do mutations reduce vaccine effectiveness in the Omicron variant?

Clinical-grade soluble human ACE2 shown to inhibit SARS-CoV-2 Omicron variant

An integrated computational methodology for COVID drug prioritization

Omicron analysis shows no clear evidence for increased virulence or lethality

At least 3 exposures to vaccine or virus needed for minimum protection against SARS-CoV-2 Omicron

3-dose vaccines deemed ultrapotent against diverse and highly transmissible SARS-CoV-2 Omicron and other variants

Researchers investigate the effect of emerging SARS-CoV-2 mutations on ACE2 binding

Study highlights importance of positive and negative selection in evolution of SARS-CoV-2 variants

Pre-existing immunity against influenza can lower SARS-CoV-2 infection burden and spread

Study suggests spike mutation makes SARS-CoV-2 Omicron milder

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News